TERN-501 Monotherapy and Combination Therapy with TERN-101 in Metabolic Dysfunction-Associated Steatohepatitis: The Randomized Phase IIa DUET Trial

DUET was a 12-week, randomized, double-blind, placebo-controlled, multicenter Phase IIa study investigating the efficacy, safety, and pharmacodynamics and pharmacokinetics of once-daily TERN-501 as monotherapy or combined with TERN-101, in patients with presumed metabolic dysfunction-associated steatohepatitis.